Rui Jing Jiang is the Founder and CEO of Avisi Technologies, a Redwood City-based clinical-stage medical device company developing VisiPlate, the world's thinnest freestanding ophthalmic implant for treating glaucoma. Built on University of Pennsylvania nanotechnology, VisiPlate is a multichannel aqueous shunt composed of alumina and Parylene-C that is 20 times thinner than a human hair. Rui Jing co-founded the company in 2017 as a junior at Penn's Wharton School, won the $100,000 President's Innovation Prize in 2018, secured FDA Investigational Device Exemption approval in October 2025 for the US SAPPHIRE trial, and closed a $10.7M Series A in February 2026 to advance pivotal clinical development.
Matt Goldman is a General Partner at J2 Ventures, a Boston-based early-stage VC firm backing dual-use technologies at the intersection of commercial markets and U.S. national security. A retired U.S. Air Force Colonel with 22+ years of service, he served as the founding Chief Medical Officer of the Defense Innovation Unit (DIU), bridging commercial innovation with defense applications. Simultaneously, he is a practicing pediatric gastroenterologist and Clinical Assistant Professor at Stanford Children's Health - an almost singular combination of MD, military officer, and venture capitalist. J2 Ventures has raised three funds totaling $468M+ and backed 35+ startups including two unicorns: Oura and Apex Space.
Josephine Chen is a Partner at Sequoia Capital focused on seed and Series A investments at the intersection of enterprise software, fintech, and crypto. Born in Massachusetts and raised largely in Taiwan before moving to the Bay Area at age ten, she brings a biomedical informatics background from Stanford and a career arc through Genentech, McKinsey, and Emergence Capital. She champions immigrant founders, bets on biology-meets-software breakthroughs, and has backed companies including Found, AMP Robotics, Anrok, Cresta, Abby Care, and Magic Eden.